Delivery Order SPE2DB22D1017-SPE2DB25FF2ZX

Award Date 1/13/25
Potential Completion Date 1/14/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,830.62, is a Firm Fixed Price Delivery Order for the pharmaceutical product Ozempic, a specialty medication used to treat diabetes. The contract has an ultimate completion date of June 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of Ozempic medication, a diabetes treatment. The contract has a ceiling value of $12,343.81 and an ultimate completion date of October 22, 2024. It is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a prescription medication used to treat diabetes. The $31,146.77 firm fixed-price contract runs through July 15, 2024. AmerisourceBergen holds a much larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a broad range of pharmaceutical products and medical supplies...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, valued at $16,177.50. The order has an ultimate completion date of January 30, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a medication used to treat diabetes. The contract has a ceiling value of $1,040.25 and a period of performance through July 17, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, and has a ceiling value of $31,941.53. It is a delivery order contract with a firm fixed price. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,023.63 firm fixed-price delivery order covers the supply of the drug Ozempic, a specialty medication used for diabetes management. The contract has an ultimate completion date of January 28, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of Ozempic, a specialty medication used to treat diabetes, with a ceiling value of $7,244.95. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at $999,999,999 and running through November...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for $2,177.06 and covers the delivery of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a diabetes medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 9, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,454.66 firm fixed-price contract is for the supply of Ozempic, a diabetes medication, with a completion date of December 11, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF2ZX
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract, valued at $11,208.44, is a Firm Fixed Price Delivery Order with a performance period through January 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award reviewed was not designated with a set-aside requirement, indicating open competition.

Generated 5/21/25, 10:09 AM